Ramucirumab is a targeted monoclonal antibody used to treat selected advanced cancers, usually after previous treatment has stopped working or is no longer suitable. It is administered by intravenous infusion and may be used alone or with other cancer medicines.
| Generic Name | Ramucirumab |
| Strength | 500 mg |
| Manufacturer | Eli Lilly and Company |
| Packing | 1 vial |
| Prescribed For | Gastric cancer |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, Japan, UAE, Saudi Arabia, Qatar, Kuwait, Georgia, Mexico, and many other countries. |




Ramucirumab attaches to vascular endothelial growth factor receptor 2, or VEGFR-2. By blocking this receptor, it prevents tumours from developing new blood vessels. Reducing their blood and nutrient supply can slow cancer growth and spread.